^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RNF43 mutation

    i
    Other names: RNF43, Ring Finger Protein 43, RING-Type E3 Ubiquitin Transferase RNF43, E3 Ubiquitin-Protein Ligase RNF43, RING Finger Protein 43, EC 2.3.2.27, RNF124
    Entrez ID:
    54894
    Related biomarkers:
    Expression
    Mutation
    Others
    11ms
    A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) (clinicaltrials.gov)
    P1, N=70, Active, not recruiting, Eisai Co., Ltd. | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    RNF43 (Ring Finger Protein 43) • APC (APC Regulator Of WNT Signaling Pathway) • AXIN1 (Axin 1) • ZNRF3 (Zinc And Ring Finger 3)
    |
    APC mutation • CTNNB1 mutation • RNF43 mutation
    |
    E7386
    11ms
    Comprehensive characterization of MCL-1 in patients with colorectal cancer: Expression, molecular profiles, and outcomes. (PubMed, Int J Cancer)
    Our data showed a strong correlation between MCL-1 and distinct immune biomarkers and TME CI in CRC. Our findings suggest MCL-1 is a potential modulator of antitumor immunity, TME, and biomarker in CRC.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • BCL2 (B-cell CLL/lymphoma 2) • STK11 (Serine/threonine kinase 11) • ASXL1 (ASXL Transcriptional Regulator 1) • MCL1 (Myeloid cell leukemia 1) • KMT2D (Lysine Methyltransferase 2D) • MSH6 (MutS homolog 6) • RNF43 (Ring Finger Protein 43) • BCOR (BCL6 Corepressor) • KDM6A (Lysine Demethylase 6A) • GNAS (GNAS Complex Locus) • CDKN1B (Cyclin dependent kinase inhibitor 1B)
    |
    TP53 mutation • KRAS mutation • TMB-H • MSI-H/dMMR • NRAS mutation • ATM mutation • STK11 mutation • RNF43 mutation • MCL1 expression
    12ms
    Lack of dominant-negative activity for tumor-related ZNRF3 missense mutations at endogenous levels. (PubMed, Oncogene)
    When representative variants are heterozygously introduced into endogenous ZNRF3, their impact on β-catenin signaling mirrors that of heterozygous knockout, suggesting that the supposed dominant-negative effect is non-existent. In other words, so-called "hyperactivating" ZNRF3/RNF43 mutations behave as classical loss-of-function mutations at endogenous levels.
    Journal
    |
    RNF43 (Ring Finger Protein 43) • RSPO1 (R-Spondin 1) • ZNRF3 (Zinc And Ring Finger 3)
    |
    RNF43 mutation
    1year
    Gender-Based Differences in the Efficacy of Anti-EGFR/BRAF/MEK Targeted Therapy in Patients with BRAF-Mutated Metastatic Colorectal Cancer. (PubMed, Semin Oncol)
    We confirmed a significant gender-based dimorphism in the efficacy of anti-EGFR/BRAF/MEK therapy in patients with advanced-CRC harboring BRAF mutations that warrant further investigation.
    Journal • Metastases
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • RNF43 (Ring Finger Protein 43)
    |
    BRAF V600E • BRAF mutation • BRAF V600 • RNF43 mutation
    1year
    Co-occurring mutations identify prognostic subgroups of microsatellite stable colorectal cancer. (PubMed, Mol Cancer)
    We report a genome-wide evaluation of co-occurring mutations in MSS CRCs, and suggest that co-mutations can improve the prognostic stratification compared to single mutations alone.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RNF43 (Ring Finger Protein 43) • APC (APC Regulator Of WNT Signaling Pathway) • SOX9 (SRY-Box Transcription Factor 9) • TCF7L2 (Transcription Factor 7 Like 2)
    |
    TP53 mutation • BRAF V600E • KRAS mutation • PIK3CA mutation • BRAF V600 • APC mutation • RNF43 mutation
    |
    MSK-IMPACT
    1year
    RNF43 and ZNRF3: Versatile regulators at the membrane and their role in cancer. (PubMed, Biochim Biophys Acta Rev Cancer)
    Additionally, we describe in detail how phosphorylation and ubiquitination may finetune RNF43 and ZNRF3 activity. We also address the variety of mutations observed in cancers and the mechanism through which they support tumor growth, and challenge the prevailing view that specific missense mutations in the R-spondin and RING domains may possess dominant-negative activity in contributing to tumor formation.
    Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • RNF43 (Ring Finger Protein 43) • RSPO1 (R-Spondin 1) • ZNRF3 (Zinc And Ring Finger 3)
    |
    RNF43 mutation
    1year
    Analysis of actionable gene fusions in a large cohort of Chinese patients with colorectal cancer. (PubMed, Gastroenterol Rep (Oxf))
    Actionable gene fusions are more prevalent in MSI-H, RAS/BRAF wildtype, or RNF43-mutated CRC, as well as in colon cancer. Mapping of these molecular markers can markedly increase the fusion detection rate, which can help clinicians select candidates for fusion testing and targeted therapy.
    Journal • MSi-H Biomarker
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • RNF43 (Ring Finger Protein 43) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR • BRAF mutation • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • BRAF wild-type • RAS mutation • RNF43 mutation • NTRK fusion
    1year
    Predictive genomic and transcriptomic analysis on endoscopic ultrasound-guided fine needle aspiration materials from primary pancreatic adenocarcinoma: a prospective multicentre study. (PubMed, EBioMedicine)
    The combination of genomic and transcriptomic analyses of primary pancreatic tumours enables us to distinguish metastatic tumours from other tumour types. Our molecular strategy may assist in predicting overall survival outcomes for platinum or gemcitabine-based chemotherapies, as well as radio-chemotherapy.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • HRD (Homologous Recombination Deficiency) • RNF43 (Ring Finger Protein 43)
    |
    TP53 mutation • KRAS mutation • HRD • TP53 wild-type • RNF43 mutation
    |
    gemcitabine
    1year
    A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands (clinicaltrials.gov)
    P1, N=185, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed
    Trial completion
    |
    BRAF (B-raf proto-oncogene) • RNF43 (Ring Finger Protein 43)
    |
    BRAF mutation • RNF43 mutation
    |
    spartalizumab (PDR001) • WNT974
    1year
    Prognostic determinants in cancer survival: a multidimensional evaluation of clinical and genetic factors across 10 cancer types in the participants of Genomics England's 100,000 Genomes Project. (PubMed, Discov Oncol)
    This study provides a comprehensive view of clinicopathological and genetic prognostic factors across different cancer types and draws attention to less commonly known factors which might help produce more precise prognosis and survival estimates. The results from this study contribute to the understanding of cancer disease and could be used by researchers to develop complex prognostic models, which in turn could help predict cancer prognosis more accurately and improve patient outcomes.
    Journal • Tumor mutational burden
    |
    BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • MSH6 (MutS homolog 6) • RNF43 (Ring Finger Protein 43) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CDH1 (Cadherin 1) • FANCE (FA Complementation Group E) • GATA3 (GATA binding protein 3)
    |
    TP53 mutation • BRAF mutation • NRAS mutation • PIK3CA mutation • PTEN mutation • NF1 mutation • RNF43 mutation
    1year
    TP53 and EGFR amplification are negative predictors of overall survival in patients diagnosed with non-small cell lung cancer with brain metastases. (PubMed, Heliyon)
    Gene signatures, such as TP53 or EGFR amplification, were associated with worse survival in patients diagnosed with NSCLC-BM. These valuable findings may shed light on new strategies for the prognostic assessment of specific patient groups.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • LRP1B (LDL Receptor Related Protein 1B) • RNF43 (Ring Finger Protein 43)
    |
    TP53 mutation • EGFR amplification • RNF43 mutation • TP53 amplification
    1year
    Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration. (PubMed, Cancer Immunol Immunother)
    This retrospective real-world study confirmed the clinical benefit of durvalumab plus chemotherapy in treatment-naïve ABC patients. Peripheral sPD-L1 and CSF1R are promising prognostic biomarkers for this therapeutic strategy. Presence of ADGRB3 or RNF43 mutations could improve the stratification of immunotherapy outcomes, but further studies are warranted to explore the underlying mechanisms.
    Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    RNF43 (Ring Finger Protein 43) • CSF1R (Colony stimulating factor 1 receptor) • ADGRB3 (Adhesion G Protein-Coupled Receptor B3)
    |
    RNF43 mutation
    |
    Imfinzi (durvalumab) • gemcitabine